Connecticut’s Democratic Governor Wants Hospitals to Report 340B Earnings and Manufacturers to Resume 340B Pricing

A Connecticut state health agency under Gov. Ned Lamont (D) proposed legislation to implement certain 340B provider reporting requirements.

Connecticut’s Democratic governor wants his state’s 340B hospitals to start filing annual reports disclosing their 340B drug revenues and summarizing how they use the money to benefit their communities. Health centers and other 340B grantee covered entities would be exempt

Read More »

Baldwin, a 340B Entity Ally, Will Chair Senate Health Appropriations Subcommittee

Sen. Tammy Baldwin (D-WI)
U.S. Sen. Tammy Baldwin (D-Wis.) is the new chair of the Senate Labor, Health and Human Services, Education, and Related Agencies Appropriations Subcommittee.

U.S. Sen. Tammy Baldwin (D-Wis.), who has a long track record of support for 340B covered entities, is the new leader of a Senate Appropriations subcommittee with influence over 340B policy.

Baldwin announced yesterday she will serve as chair

Read More »

340B Pricing May Be Coming to Contrast Agents, Radiopharmaceuticals, and OTC Monograph Drugs

Contrast media image of kidneys
Providers may get previously unavailable access to 340B pricing on contrast agents, radiopharmaceuticals, and OTC monograph drugs thanks to language in a a federal FY 2023 spending law.

Health care providers in the coming months may get previously unavailable access to 340B pricing on contrast agents, radiopharmaceuticals, and so-called “OTC monograph” drugs thanks to language tucked into the massive fiscal year 2023 federal spending bill signed into law

Read More »

Ex-CMS Leader Verma: Big Health Systems Use 340B to Expand Profit and Monopoly Power

CMS Administrator Seema Verma speaks at White House podium
Health systems use 340B to expand "their profit and monopoly power," Trump administration CMS Administrator Seema Verma said in a Wall Street Journal op-ed.

Seema Verma, ex-President Trump’s Centers for Medicare & Medicaid Services administrator, said in a Wall Street Journal op-ed yesterday that large health systems work to expand their use of the 340B program “and thus their profit and monopoly power.”

“Across

Read More »

CMS Seeks Input on Excluding 340B Drugs from New Medicare Part D Inflation Rebates

Part D inflation rebate press release
CMS is seeking comment on how best to exclude 340B drugs from new Part D inflation rebate invoices.

The U.S. Centers for Medicare & Medicaid Services is seeking comments by March 11 on “the most reliable way to identify” 340B-purchased drugs dispensed to Medicare Part D beneficiaries so they can be excluded from new Part D inflation rebate

Read More »

Sanders, Asked About Abuse in 340B, Cites His Past Effort to End a Hospital’s Tax Exemption

Sen. Bernie Sanders speaking at a podium
Senate HELP chair Bernie Sanders (I-Vt.) talked about taking away hospitals' tax-exempt status when he was asked during an interview about alleged hospital abuse of 340B.

U.S. Sen. Bernie Sanders (I-Vt.), the new chair of the Senate committee that oversees the 340B program, recently answered a reporter’s question about alleged hospital abuse of 340B by noting that he tried to revoke a Burlington, Vt., hospital’s tax-exempt

Read More »

More Entities Might Share 340B Contract Pharmacy Claims Data if the Process Improves and Actually Restores 340B Pricing, Survey Shows

laptop screen depicting data upload
More 340B entities would share contract pharmacy claims data with manufacturers if the process was better and got 340B pricing turned back on reliably, a survey by McKesson found.

While most 340B covered entities do not share their contract pharmacy claims data with drug makers to restore access to 340B pricing, many would do so if the process was better and got 340B pricing turned back on reliably, a

Read More »

340B Stakeholders Weigh in on HRSA’s Proposal to Replace 340B Dispute Resolution Process

Screenshot of regulations.gov 340B drug pricing program ADR document details.
340B contract pharmacy loomed large in stakeholders’ comments on HRSA's proposed revamp of the 340B program’s administrative dispute resolution system.

The fight over 340B contract pharmacy loomed large in stakeholders’ comments last week on a proposed federal regulation to revamp the 340B program’s administrative dispute resolution system.

Health care provider groups, citing manufacturers’ contract pharmacy policies, said they want the

Read More »

Bayer: 340B “Is Enriching Middlemen Versus Benefitting Patients”

Bayer wordmark on building
Bayer added a previously excluded drug to its list of products that face contract pharmacy restrictions.

While the 340B program “has merit when used as intended,” it has “strayed far from its original purpose, creating a profit stream that is enriching middlemen versus benefitting patients,” drug manufacturer Bayer told 340B Report yesterday.

Bayer gave the statement

Read More »

Upcoming End of COVID-19 Emergency Could Prompt HRSA to End or Scale Back 340B Flexibilities

COVID-19 PHE sign with beach in background
The Biden administration plans to end the nationwide COVID-19 public health emergency on May 11.

The Biden administration said on Monday that it plans to end the nationwide COVID-19 public health emergency on May 11. When the PHE ends, COVID-related 340B program flexibilities announced in March 2020 could end too.

The U.S. Health Resources and

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live